Please assess the completion status of the following clinical trial:

Trial Title: Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diffuse large B-cell lymphoma~  * B-cell phenotype (CD20+) as determined by immunohistochemistry (IHC) or flow cytometry~ * Stage II, III, or IV disease~* CD22+ tumor by IHC\*~NOTE: \*CD22 status may be determined after study enrollment~* Measurable disease, defined as at least 1 lesion ≥ 1.5 cm by CT scan or physical exam~* No relapsed or refractory non-Hodgkin's lymphoma~* No history of transformed lymphoma~* No CNS lymphoma~  * CNS symptoms or bone marrow or sinus involvement must have absence of CNS lymphoma confirmed by lumbar puncture~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-3~  - For patients with ECOG PS 3, the PS must be disease related~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Total bilirubin ≤ 2 mg/dL (if total bilirubin \> 2 mg/dL, direct bilirubin should be within normal limits)~* AST ≤ 3 times upper limit of normal (ULN) (5 times ULN if there is liver involvement)~* Creatinine ≤ 2 times ULN~* Life expectancy ≥ 12 weeks~* Negative pregnancy test~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 12 months after completion of study treatment~* No active serious infection requiring antibiotics~* No New York Heart Association class III or IV heart disease~* No other primary malignancy within the past 5 years, except for squamous cell or basal cell carcinoma of the skin, in situ carcinoma of the cervix, or previously treated prostate cancer with a stable prostate-specific antigen~* No known HIV positivity~* No known hepatitis B or C infection~* Ejection fraction ≥ 45% by MUGA or echocardiogram (required if patients has a history of heart disease or is ≥ 50 years old)~* Willing to provide blood and tissue samples for mandatory translational research component of study~PRIOR CONCURRENT THERAPY:~* No prior therapy for diffuse large B-cell lymphoma, including the following:~  * Chemotherapy~ * Immunotherapy~ * Biologic therapy~ * Radiotherapy~* Prior short course (≤ 14 days) of corticosteroids allowed~* Prior splenectomy allowed~* No prior pelvic irradiation~* No other concurrent investigational agents~* No concurrent chemotherapy, immunotherapy, or radiotherapy~* No concurrent enrollment on another treatment study involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy, or gene therapy)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Epratuzumab + Rituximab + CHOP (Type: EXPERIMENTAL): One arm open label.

Based on this trial design, predict the completion outcome and termination type (if applicable).